SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla - Quaterly Results

22 Jan 2024 Evaluate
The company witnessed a 23.92% growth in the revenue at Rs. 43813.30 millions for the quarter ended December 2023 as compared to Rs. 35357.30 millions during the year-ago period.The Profit  for the quarter ended December 2023 of  Rs. 10177.60  millions  grew by 70.30% from Rs. 5976.20 millions.OP of the company witnessed a marginal growth to 15248.40 millions from 9559.30 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 43813.30 35357.30 23.92 133642.40 115331.40 15.88 157906.00 153808.20 2.66
Other Income 1689.80 1271.20 32.93 5320.50 3370.80 57.84 4567.90 6667.00 -31.48
PBIDT 15248.40 9559.30 59.51 44717.20 32205.80 38.85 42493.70 43779.30 -2.94
Interest 90.60 56.60 60.07 171.70 153.70 11.71 270.20 269.30 0.33
PBDT 15157.80 9502.70 59.51 44545.50 32052.10 38.98 40364.50 43510.00 -7.23
Depreciation 1350.20 1299.60 3.89 4507.80 4343.30 3.79 5959.10 5466.20 9.02
PBT 13807.60 8203.10 68.32 40037.70 27708.80 44.49 34405.40 38043.80 -9.56
TAX 3630.00 2226.90 63.01 10613.00 7377.40 43.86 9710.10 9218.00 5.34
Deferred Tax 143.10 80.20 78.43 40.60 -15.10 -368.87 -400.90 -276.90 44.78
PAT 10177.60 5976.20 70.30 29424.70 20331.40 44.73 24695.30 28825.80 -14.33
Equity 1614.70 1614.30 0.02 1614.70 1614.30 0.02 1614.30 1613.60 0.04
PBIDTM(%) 34.80 27.04 28.73 33.46 27.92 19.82 26.91 28.46 -5.46

Cipla Share Price

1238.30 7.55 (0.61%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×